{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-050412","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2021-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.133755+00:00","generated_at":"2026-06-28T22:20:28.678076+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nkarta doses first patients in NKX019 Ph1; NKX101 initial data guided to 1H 2022","bullets":["First patients dosed in Phase 1 trial of NKX019 for CD19+ B-cell malignancies (NHL, CLL, B-ALL).","Initial data from NKX019 trial expected in 2022.","Initial data from NKX101 Phase 1 in AML/MDS now expected in first half of 2022 (previously anticipated earlier).","NKX101 cadence affected by haplomatched donor cell use, staggered enrollment, and COVID-19 disruptions.","Protocol amended to allow off-the-shelf or haplomatched cells and to shorten patient stagger."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-050412","json":"https://secwatch.observer/filing/0001564590-21-050412.json","markdown":"https://secwatch.observer/filing/0001564590-21-050412.md","text":"https://secwatch.observer/filing/0001564590-21-050412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000156459021050412/0001564590-21-050412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000156459021050412/nktx-8k_20211007.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T22:20:28.678076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}